



Published in final edited form as:

*Anticancer Drugs*. 2009 March ; 20(3): 179–184. doi:10.1097/CAD.0b013e328325a867.

## A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium Study

Primo N. Lara Jr., Jeff Longmate, Christopher P. Evans, David I. Quinn, Przemyslaw Twardowski, Gurkamal Chatta, Edwin Posadas, Walter Stadler, and David R. Gandara  
University of California Davis Cancer Center, Sacramento, CA (PNL, CPE, DRG); Veterans' Administration of Northern California, Mather, CA (PNL); City of Hope Comprehensive Cancer Center, Duarte, CA (JL, PT); University of Southern California Norris Cancer Center, Los Angeles, CA (DIQ); University of Pittsburgh Cancer Center, Pittsburgh, PA (GC); University of Chicago Cancer Center (EP, WS)

### Abstract

**Background**—Prostate cancer cells undergo neuroendocrine differentiation during androgen deprivation and secrete neuropeptides, hence activating androgen receptor-regulated genes. Src family protein kinases are involved in neuropeptide-induced prostate cancer growth and migration. A phase II trial of AZD0530, an oral Src-family kinase inhibitor, in patients with advanced castration resistant prostate cancer was conducted.

**Methods**—The primary endpoint was prostate cancer specific antigen (PSA) response rate, defined as a 30% or greater decrease. A two-stage Simon design was employed. Eligibility criteria included documentation of castration resistance (including anti-androgen withdrawal), adequate end-organ function and performance status, and no more than one prior taxane-based chemotherapy regimen. AZD0530 was given at 175 mg orally once daily continuously.

**Results**—Rapid accrual led to 28 patients registering in the first stage. Median age was 67 years. Sixteen patients had performance status (PS) 0, 8 had PS 1, and 4 had PS 2. Nine patients (32%) had prior docetaxel-based chemotherapy. Five patients had transient PSA reductions not meeting PSA response criteria. Median progression-free survival time was 8 weeks. Treatment was generally well tolerated.

**Conclusion**—AZD0530, a potent oral src kinase inhibitor, is feasible and tolerable in this pre-treated patient population but possessed little clinical efficacy as monotherapy. Strong preclinical evidence warrants further investigation of AZD0530 in earlier stage prostate cancer or as combination therapy.

### Keywords

Src-inhibitor; prostate cancer; castration-resistant

### INTRODUCTION

Prostate cancer is the most common cancer in American men and the second leading cause of cancer deaths.(1) In most treatment-naïve patients with metastatic prostate cancer,

---

All correspondence should be directed to: Primo N. Lara, Jr., Professor of Medicine, University of California Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, Voice: 916.734.3771, Fax: 916.734.7946, primo.lara@ucdmc.ucdavis.edu.

ClinicalTrials.gov Identifier: NCT00513071

androgen deprivation (castration) therapy can induce substantial tumor reduction and disease control. Unfortunately, prostate cancer cells subsequently lose androgen-dependency, leading to a metastatic and androgen-independent (AI) state, often termed as castration-resistant prostate cancer (CRPC).(2) The vast majority of deaths from prostate cancer is due to castration-resistant disease.

During the transition to castration resistance, a subpopulation of neuroendocrine cells appears to expand.(3,4) Nearly all prostate cancers contain neuroendocrine cells that are identified by neurosecretory granules and expression of neuron specific markers including chromogranin A, neuro-specific enolase and mitogenic hormones such as parathyroid hormone-related peptide, bombesin/gastrin-releasing peptide (GRP), serotonin, calcitonin, and neurotensin, among others.(5–10) However, during castration therapy, more prostate cancer cells acquire neuroendocrine features and begin expressing neuropeptides. Through non-receptor tyrosine kinases, these neuropeptides activate androgen receptor regulated genes in the absence of androgens to support growth, migration and in vivo metastasis.(11) Furthermore, cytokines such as IL-6 and IL-8 have increased expression at the time of castration and induce non-receptor tyrosine kinase-mediated androgen-independent prostate cancer.(12)

Members of the Src family of protein kinases have been identified as involved in neuropeptide-induced cell growth and migration.(13) Src, the first oncogene to be identified, mediates the signaling of a number of neuropeptide receptors and is involved in formation of focal adhesions and enhanced cellular migration. Src regulates signaling pathways involving survival, angiogenesis, steroid receptor activation, and growth factor receptors.(14) Increased Src activity appears to correlate with disease progression. Additionally, it has been reported that Src is not only activated in androgen-sensitive LNCaP cells upon androgen withdrawal, but is constitutively activated in several castration-resistant cell lines.(15) Novel agents that modulate the Src-kinase pathway offer the potential for therapeutic advances in castration-resistant prostate cancer.

AZD0530 is a novel, orally bioavailable aniline-quinazoline that has been shown to modulate cellular pathways involving the Src family of kinases. AZD0530 is highly selective for non-receptor tyrosine kinases with IC<sub>50</sub> values in the nanomolar (nM) range for several targets, including c-Src (2.7 nM), c-Yes (4 nM), Lck (<4 nM), and Bcr-Abl (30 nM). In non-clinical models, AZD0530 has demonstrated potent effects on cell motility, invasion, and metastasis. It is a dual-specific inhibitor that acts through ATP competitive and reversible inhibition of target enzymes. Preclinical work with AZD0530 in prostate cancer cell lines (LNCaP, PC3, DU145 and CWR22R) showed that all lines expressed phospho-Src and treatment with AZD0530 (5µM) inhibited Src activation.(16) In an in-vivo murine xenograft model of neuroendocrine prostate cancer, AZD0530 was found to inhibit tumor Src phosphorylation as well as tumor growth in a dose-dependent manner. Additionally, prostate cancer cell migration was decreased by AZD0530 through phospho-FAK inhibition.

A phase I clinical trial demonstrated the feasibility and tolerability of AZD0530 treatment in patients with advanced solid malignancies, and provided the first demonstration of pharmacological Src inhibition in tumor tissue of patients with cancer.(17) In light of these results, and the preclinical evidence of activity in prostate cancer, we conducted a phase II trial of AZD0530 in patients with advanced, castration-resistant prostate cancer.

## PATIENTS AND METHODS

### Eligibility Criteria

To be eligible, all patients must have had a histologic diagnosis of adenocarcinoma of the prostate that was unresponsive or refractory to hormone therapy (despite androgen deprivation and anti-androgen withdrawal when applicable) as defined by at least one of the following criteria: 1) Progression of unidimensionally measurable disease assessed within 28 days prior to initial administration of drug; 2) Progression of evaluable but not measurable disease assessed within 28 days prior to initial administration of drug for PSA evaluation and within 42 days for imaging studies; 3) Rising PSA, defined as at least two consecutive rises in PSA to be documented over a reference value (measure 1). The first rising PSA (measure 2) should be taken at least 7 days after the reference value. A third confirmatory PSA measure (2<sup>nd</sup> beyond the reference level) should be greater than the second measure, and it must be obtained at least 7 days after the 2<sup>nd</sup> measure. If this was not the case, a fourth PSA was required to be taken and be greater than the second measure. A minimum PSA was not required. Measurable disease was also not required. However, patients who had measurable disease must have had X-rays, scans or physical examinations used for tumor measurement completed within 28 days prior to initial administration of drug. Patients must have non-measurable disease (such as nuclear medicine bone scans) and non-target lesions (such as PSA level) assessed within 28 days prior to initial administration of drug.

Patients must have been surgically or medically castrated with medical castration continuing throughout protocol therapy and serum testosterone at castrate levels (< 50 ng/dL) at least 3 months prior to registration. One (and only one) prior taxane-based chemotherapy was allowed. At least three weeks must have elapsed since the completion of the chemotherapy, and the patient must have recovered from the side effects of the therapy. If the patient has been treated with non-steroidal anti-androgens (such as flutamide, bicalutamide or nilutamide) or other hormonal treatment (such as ketoconazole), these agents must have been stopped at least 28 days prior to enrollment for flutamide or ketoconazole, and at least 42 days prior to enrollment for bicalutamide or nilutamide; and the patients must have demonstrated progression of disease since the agents were suspended. Patients were required to have a Zubrod performance status of 0–2 and normal end-organ (hepatic, renal) and marrow function, determined within 14 days of registration. Concurrent bisphosphonate therapy was allowed. Patients must have agreed to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. All patients were to have an ability to understand and the willingness to sign a written informed consent document prior to study entry.

Patients who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier were excluded. Use of specifically prohibited CYP3A4-active agents or substances was not permitted during protocol treatment, and patients who must continue treatment with these agents were deemed ineligible. Also excluded were those with brain metastases, uncontrolled intercurrent illness, and HIV-positive patients on combination antiretroviral drugs.

### Treatment Plan

Patients were treated with AZD0530 administered at 175 mg per day (one 125-mg tablet plus one 50-mg tablet) by mouth continuously. AZD0530 was to be taken at approximately the same time each morning, either 1 hour before or 2 hours after eating. The tablets were not to be chewed, crushed, or broken. Cycle length was arbitrarily defined as 4 weeks.

Toxicities were assessed using the National Cancer Institute's Common Toxicity Criteria (version 3). In the absence of unacceptable toxicity or clear clinical progression, the patient received a minimum of two cycles of treatment. If a patient developed progressive disease after two cycles of therapy, that patient was removed from the protocol. In the absence of progression, the patient continued on protocol until unacceptable toxicity or other reason for discontinuation occurred. Criteria for removal from protocol therapy included progression of disease, unacceptable toxicity, withdrawal of patient consent, and delay of treatment greater than four weeks from planned date of therapy due to toxicity.

### Response Assessment

Response was assessed using RECIST criteria which were modified to incorporate consensus recommendations on assessing response by PSA levels. All disease must have been assessed using the same technique as baseline. Complete response (CR) was defined as "complete disappearance of all measurable and non-measurable disease with no new lesions, no disease related symptoms, normalization of markers and other abnormal lab values, and PSA < 0.2 ng/mL. Partial Response (PR) was defined by either of the two sets of criteria: 1) Greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions, with no new lesions, and no unequivocal progression of non-measurable disease; or 2) A decline in PSA by at least 30%, confirmed by a second PSA value four or more weeks later with the reference PSA for these declines being a PSA measured within three weeks prior to starting therapy and patients not demonstrating clinical or radiographic evidence of progression of measurable or non-measurable disease during this time period. Stable disease was defined as not qualifying for CR, PR, Progression or Symptomatic Deterioration. Progressive disease was noted when one or more of the following occurred: 1) 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline; 2) Increase in PSA by at least 25% (by at least 5 ng/mL) over baseline; 3) Unequivocal progression of non-measurable disease in the opinion of the treating physician; 4) Appearance of any new lesion/site; or 5) Death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration was defined as global deterioration of health status requiring discontinuation of treatment without objective evidence of progression.

### Statistical Considerations

The primary endpoint for this trial was PSA response rate. A 30% reduction in the PSA level from baseline was to be considered a favorable outcome. A 30% reduction was selected as the principal response discriminant instead of 50% as per the 1999 consensus criteria(18) because of recent data from the SWOG 9916 trial of docetaxel/estramustine versus mitoxantrone/prednisone demonstrating that it was the 30% level which met Prentice's criteria for survival surrogacy.(19) However, patients experiencing a greater than or equal to 50% reduction in PSA level, as per consensus criteria, were also be recorded in the database. A response rate of 15% following treatment with AZD0530 alone would be considered evidence of activity and encouraging of further study, whereas a response rate of less than 2% would be considered uninteresting as a single agent unless the secondary endpoint of PFS was encouraging. To evaluate the response rate a two-stage was used. Patients who complete 1 cycle of therapy, or who terminate treatment for reasons of toxicity, or who progress prior to completion of 1 cycle of therapy, were to be included in the analysis of response. The probability of falsely declaring a regimen with a discouraging response rate as warranting further study is 0.04 (alpha) and the probability of correctly declaring the agent warranting further study was greater than 0.91 (power) based on the following design: In the first stage, 18 patients were to be accrued, and if there were no responders the study would terminate early. Otherwise accrual would proceed to 40 patients. If 3 or more responses

were observed in the 40 patients, that would be considered evidence warranting further study of the schedule providing other factors, such as toxicity and time to progression, also appeared favorable. If less than 3 responses were observed in the 40 patients, further study of this schedule of AZD0530 would not be warranted based on the criteria of response rate. No break in accrual between stages was planned. With 40 evaluable patients, the 95% confidence interval for the response rate would have a half-width of +15% or less. If the primary endpoint was not encouraging, AZD0530 would still be considered promising as a single agent if PFS looked encouraging. Specifically, all patients were expected to progress (including PSA Progression) without chemotherapy within 3 months.<sup>(20)</sup> For a one-sample, one-sided, 0.05-level test using the large-sample normal approximation for the distribution of the logarithm of the maximum likelihood estimator of the exponential parameter, there was 91% power to detect an improvement in median PFS to 5 months from the null hypothesis that the median PFS is 3 months based on 12 month accrual and 6 months of follow-up. Parametric estimate of the median survival exceeding 4 months would have been sufficient to rule out the null hypothesis given the sample size of 40 patients. If the median PFS survival (estimate using a parametric method) is in excess of 4 months, AZD0530 would be considered promising based on this secondary endpoint.

## RESULTS

### Patient Characteristics

A total of 28 eligible patients were enrolled between August 2007 and November 2007. Accrual beyond the first stage cutoff of 18 patients was due to rapid simultaneous accrual in this multi-institutional study. Patient characteristics are summarized in Table 1. Median age was 67 years, with a range of 50 to 84 years. Sixteen patients had performance status (PS) 0, 8 had PS 1, and 4 had PS 2. Nineteen patients had received prior radiation therapy.

### Efficacy

Although five patients had slight PSA reductions, none of these were durable nor met the PSA response criteria of >30% from baseline. One patient had a PSA decline from 81 ng/mL to 67 ng/mL at cycle 3, then went back up to 85 ng/mL. Another had a PSA drop from 997 ng/mL to 906 ng/mL at cycle 1, with no additional data available. One patient had a PSA decline from 122 ng/mL to 94 ng/mL at cycle 2, then went back up to 122 ng/mL. One patient had a PSA drop from 3.8 ng/mL to 2.9 ng/mL (baseline versus cycle 2) then back to 3.9 ng/mL at the very next assessment. Finally, another patient had a PSA decline from 10270 ng/mL to 8392 ng/mL from cycle 1 to 2 but had symptomatic progression shortly thereafter, requiring protocol discontinuation. Median progression free survival was 8 weeks. Only three patients were progression-free beyond 20 weeks with PSA levels within 50% of baseline values.

### Toxicity

Attributable toxicities exceeding CTC grade 3 are reported in Table 2. AZD0530 was generally well-tolerated, with few moderate to severe toxicities. One grade 3 occurrence each of alanine transaminase (ALT), aspartate transaminase, nausea, vomiting, and lymphopenia were reported. One patient with pre-existing metabolic syndrome died unexpectedly at home while on cycle 1 of therapy. No autopsy was performed. AZD0530 treatment was listed as a possible cause along with diabetes mellitus, morbid obesity, hypertension, hypercholesterolemia, and renal failure.

## DISCUSSION

The role of Src family kinases in prostate carcinogenesis and the transition to androgen independence has only recently been described. It has been shown by our group that Src kinase is critical for androgen-independent activation of androgen receptor pathways mediated by neuropeptides.(21) Our preclinical studies demonstrated the involvement of both Src and the Src-substrate focal adhesion kinase (FAK) in the IL-8-induced migration of the LNCaP cell line. Moreover, androgen-independent growth and cell migration of various prostate cancer cell lines are inhibited by the Src-inhibitors 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) and dasatinib.(22–24) In addition, these and other studies have shown that alternative pathways (e.g., those mediating angiogenesis, cell survival, and neuroendocrine differentiation) are able to activate the androgen receptor in the milieu of androgen deprivation, effectively negating the growth inhibitory effects of that therapy.(25–27) Hence targeting the Src-family of kinases (which modulate neurotrophic-mediated androgen receptor activation) appears to offer a unique platform on which to develop targeted therapy in advanced prostate cancer.

Despite promising preclinical data, this phase II trial of the orally bioavailable Src-kinase inhibitor AZD0530 in patients with established castration-refractory prostate cancer did not demonstrate any durable effects on PSA levels or progression-free survival. One potential explanation for these results is that this single agent was clinically tested in a prostate cancer population that was least likely to benefit: patients with established, previously-treated metastatic disease. In this heavily pre-treated group, inhibition of the Src kinase family was likely insufficient in the face of already established alternative signaling pathways and resistance mechanisms. Instead, future investigations of this agent might be more relevantly applied to patients with substantially lower metastatic burden, such as those with biochemically recurrent prostate cancer while on androgen deprivation. In light of the anti-metastatic potential of Src-kinase inhibition, AZD0530 might also be reasonably tested in patients with even earlier stage disease (e.g., biochemical failure following definitive local therapy or in high risk patients after definitive local therapy). Studies of AZD0530 in combination with other established systemic therapies such as cytotoxic chemotherapy can also be considered.

AZD0530 also has bone-metabolism modulating properties. It is known that inhibition or deletion of c-Src impairs the function of bone-resorbing osteoclasts and that AZD0530 modulates osteoclast homeostasis.(28) Our own group has shown that Id family genes are implicated in this pathway. In this work, Src was found to be a requirement for bone morphogenetic protein-2 (BMP-2)-induced Id1 expression and promoter activity. It is known that BMP family members have critical roles in normal bone and cartilage development.(29) We have shown that Id family genes are down-regulated by incubation of A549 lung carcinoma cells with AZD0530.(30) Furthermore, Id1 transcript and protein levels were significantly reduced in a dose-dependent manner as were activated Src levels. AZD0530 and Id1 siRNA subsequently decreased cancer cell invasion, which was increased by Id1 overexpression. These and other encouraging preclinical work suggest that AZD0530 has a potential to be tested in the context of bone health in cancer patients, mediated through BMP family members, in addition to its antineoplastic properties.

In summary, AZD0530 was unable to induce durable PSA responses in this trial of pre-treated patients with advanced castration-resistant prostate cancer. AZD0530 does have biologic activity against prostate cancer, as evidenced by strong preclinical evidence and perhaps transient PSA reductions in five patients enrolled in this present study. Further evaluation of AZD0530, particularly in earlier stage prostate cancer, may be warranted.

## Acknowledgments

Supported by: N01-CM62209 (California Cancer Consortium); NOI-CM17102 (University of Chicago Consortium). We also acknowledge the support of the Cancer Therapy Evaluation Program (Dr. John Wright) of the National Cancer Institute in the development and conduct of this trial.

## References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. *CA Cancer J Clin*. 2008 Mar–Apr; 58(2):71–96. [PubMed: 18287387]
2. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. *Urology*. 2000; 55(3):323–327. [PubMed: 10699601]
3. Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S. *Prostate Supplement*. 1998; 8:52–61. [PubMed: 9690664]
4. Bostwick DG, Dousa MK, Crawford BG, Wollan PC. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. *Am J Surg Pathol*. 1994; 18(12):1240–1246. [PubMed: 7977947]
5. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinomas. *J Urology*. 1991; 146:358–361.
6. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. *Prostate*. 1988; 12:39–46. [PubMed: 2450341]
7. Dalsgaard CJ, Hultgardh-Nilsson A, Haegerstrand A, Nilsson J. Neuropeptides as growth factors. Possible roles in human diseases. *Regulatory Peptides*. 1989; 25:1–9. [PubMed: 2655036]
8. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. *Urology*. 1994; 43:675–679. [PubMed: 8165768]
9. Willey JC, Lechner JF, Harris CC. Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells. *Experimental Cell Research*. 1984; 153:245–248. [PubMed: 6547391]
10. Seuwen K, Pouyssegur J. Serotonin as a growth factor. *Biochemical Pharmacology*. 1990; 39:985–990. [PubMed: 2157441]
11. Yang JC, Busby JE, Kung HJ, Evans CP. Src kinase inhibition of neuropeptide-induced androgen-independent prostate cancer. *Proc Am Assoc Cancer Res*. 2005; 46:A3180.
12. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. *Nature*. 1998; 393:83–85. [PubMed: 9590694]
13. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. *Mol Cell Biol*. 2001; 21(24):8385–8397. [PubMed: 11713275]
14. Aligayer H, Boyd D, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. *Cancer*. 2002; 94:344–351. [PubMed: 11900220]
15. Desai SJ, Ma AH, Tepper CG, Chen HW, Kung HJ. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. *Cancer Res*. 2006; 66:10449–10459. [PubMed: 17079466]
16. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. *Oncogene*. 2008; 27(49):6365–6375. [PubMed: 18679417]
17. Cervantes, Tabernero A.; Hoekman, K.; Hurwitz, HI.; Jodrell, DI.; Hamberg, P., et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. *J Clin Oncol*. 2007; 25(18S):3520.
18. Bublely GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer:

- recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol.* 1999; 17:3461–3467. [PubMed: 10550143]
19. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16. *J Natl Cancer Inst.* 2006; 98(8):516–521. [PubMed: 16622120]
  20. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. *J Clin Oncol.* 1999; 17(8):2506–2513. [PubMed: 10561316]
  21. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. *Neoplasia.* 2007; 9(2):90–100. [PubMed: 17357254]
  22. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. *Oncogene.* 2001; 20:1152–1163. [PubMed: 11313859]
  23. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. *Oncogene.* 2004; 23:2197–2205. [PubMed: 14767470]
  24. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. *Cancer Res.* 2005; 65:9185–9189. [PubMed: 16230377]
  25. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. *Mol Cancer Ther.* 2006; 5:621–629. [PubMed: 16546976]
  26. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, et al. HIF-1 $\alpha$ , STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. *Oncogene.* 2005; 24:3110–3120. [PubMed: 15735682]
  27. Bang YJ, Pirmia F, Fang WG, Kang WK, Sartor O, Whitesell L, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. *Proc Natl Acad Sci USA.* 1994; 91:5330–5334. [PubMed: 8202489]
  28. Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. *Anticancer Agents Med Chem.* 2008; 8(3):342–349. [PubMed: 18393792]
  29. Cheng H, Jiang W, Phillips F, Haydon R, Peng Y, Zhou L, Luu H, An N, Breyer B, Vanichakarn P, Szatkowski J, Park J, He T. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). *J Bone Joint Surg Am.* 2003; 85-A(8):1544–1552. [PubMed: 12925636]
  30. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. Regulation of Id1 expression by Src: implications for targeting of the bone morphogenetic protein pathway in cancer. *Cancer Res.* 2008; 68(7):2250–2258. [PubMed: 18381431]



**Table 1**

## Patient Characteristics

<b>Number of patients</b>	28
<b>Age in years, median (range)</b>	67 (50–84)
<b>Race/Ethnicity (%)</b>	
Caucasian	26 (93%)
Black	2 (7%)
<b>Performance Status (%)</b>	
0	16 (57%)
1	8 (29%)
2	4 (14%)
<b>Prior docetaxel-based therapy (%)</b>	
Yes	9 (32%)
No	19 (68%)

**Table 2**

Grade 3 or Worse Toxicities (Possibly, Probably, or Definitely) Attributed to AZD0530

Toxicity	Grade	Occurrences
Alanine aminotransferase (ALT)	3	1
Aspartate aminotransferase (AST)	3	1
Nausea	3	1
Vomiting	3	1
Lymphopenia	3	1
Death, not associated with CTC term*	5	1

\* Note: One patient died unexpectedly at home. No autopsy was performed. Treatment was listed as possible cause along with diabetes mellitus, morbid obesity, hypertension, hypercholesterolemia, and renal failure.